Open access · CC-BY
via OpenAlex
Editorial: Old drugs: confronting recent advancements and challenges
Anna Wiktorowska‐Owczarek, Diego Iacono, Magdalena Jasińska-Stroschein
Frontiers in Pharmacology · 2025 · ▲ 2 citations
Abstract
IntroductionDrug repurposing involves leveraging existing drugs or drug candidates, originally developed for other conditions, to address new therapeutic purposes or medical conditions. This strategy often draws from observations of unintended or off-target effects, including those initially seen as adverse or age-specific, which may reveal their potential to alleviate chronic, degenerative, or age-related conditions. The core characteristics of drug repurposing may be summarized as follows:1. Well-Known Safety: Repurposed drugs are typically already tested for safety in humans, significantly reducing early-stage development risks.2. Streamlined Development: These drugs can bypass initial drug discovery phases, proceeding directly to preclinical or clinical trials.3. Cost and Risk Reduction: By skipping early development stages, repurposing lowers both financial costs and associated risks.4. Time Efficiency: The process offers a quicker path to market, addressing unmet medical needs efficiently.More recently, the search for repurposing candidates combines traditional and modern tools, including but not limited to computational analysis and database searches (i.e. utilizing public databases such as medical journals, regulatory agency archives, and patient advocacy group reports); newer experimental approaches (i.e., testing drug interactions in novel contexts); artificial intelligence and bioinformatics tools (i.e., advanced algorithms explore potential drug-protein interactions, integrating pharmacological data with genetics, pharmacogenomics, biological pathways, and diagnostic/prognostic insights).For the above reasons, over the years, there has been an increasing demand for a more effective and cost-efficient drug discovery process. To do so and in addition to searching for. In review entirely new molecules to be included in therapies, drug repositioning is a dynamically developing area in the search for effective therapy for many diseases. This approach is actually particularly appealing since it saves time and resources and reduces the risk of failure or unexpected safety issues.The aim of the special issue was to inspire you to present your research, but also to encourage the interested readers to review drugs whose scope of action has expanded over the years and, additionally, open up new points of entry in the treatment of various diseases. The research topic features six review articles, including one systemic review. Additionally, the collection includes four original research papers.In the original papers, commonly known drugs were analyzed, but contextualized in new applications. For example, Chen et al. searched for antiviral treatment for parainfluenza 3 (PIV3) illness. The authors explored an integrated drug repurposing method, including disease similarity and chemical similarity as multi-similarity analysis approaches, molecular docking and molecular dynamic simulation methods as structure-based screening approaches, and network proximity analysis, in which they quantified the network distance between the disease module of PIV3 and the drug targets to probe the potential anti-PIV3 drugs. Using the aforementioned method, they confirmed that oseltamivir is the best potential drug against PIV3. Therefore, they recommend considering oseltamivir for clinical application in children.The next compound analyzed for a potential new indication was rosiglitazone, which is a thiazolidinedione used in the treatment of diabetes (Lehmann et al., 1995). Rosiglitazone has been reported to ameliorate high-fat diet-induced obesity in mice (Petrovic et al., 2010). As Li et al. showed, this antidiabetic drug promotes adipocyte browning by inhibiting autophagy(definition).More specifically, inhibition of autophagy by rosiglitazone increased p62 nuclear translocation and stabilized the PPARγ-RXRα heterodimer for the transcription of browning genes. These studies underlined the promising role of rosiglitazone in the treatment of obesity. Interestingly, a new challenge has been set for dexmedetomidine (DEX), namely its participation in the protection against many degenerative conditions, including neurodegenerative diseases, by reducing oxidative stress. Indeed, DEX is a highly selective α2-adrenoceptors agonist, has a sedative, analgesic effect and anti-sympathetic properties (Keating, 2015). Lou et al. research has shown that DEX effectively reduces oxidative stress, avoids apoptosis and protects osteoblasts. The authors propose it for the prevention of bone defects, which could also be utilized though for other non-bone defects.The last of the original research tested in the diabetic retinopathy (DR) the purine analogue 6-thioguanine (6TG), an old drug approved in the 60s to treat acute myeloid leukemia (AML) – Trotta et al. The authors concluded that 6TG revealed a marked anti-angiogenic activity in HUVECs exposed to high glucose and in mice with DR, and this activity was mediated by MC1R and MC5R retinal receptors.In turn, review papers considered the possibility of repurposing effect of cardiovascular-metabolic drugs to prolong life (Barinda et al.). This systematic review mainly addressed to animal models (short-lived, obese or diabetic mice), where numerous cardiovascular, antidiabetic and lipid-lowering medications proved to successfully extend the lifespan. The authors also provide summary of ongoing clinical trial in repurposing cardiometabolic drug (metformin, omega-3 fatty acid, acarbose, and atorvastatin) for aging, expressing an expectation that the obtained findings will give the support for the utility of these medications in healthy subjects’ cardiovascular or neurological aging. The pleiotropic effects exerted by statins and beta-blockers gave the rationale to evaluate their possible complementary use in solid tumours, including breast, colorectal, lung, and prostate cancers (Braga et al.). The authors provided an update of the impact of these therapies on cancer treatment and surveillance
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fphar.2025.1565890
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Wiktorowska‐Owczarek, A., Iacono, D., & Jasińska-Stroschein, M. (2025). Editorial: Old drugs: confronting recent advancements and challenges. <em>Frontiers in Pharmacology</em>. https://doi.org/10.3389/fphar.2025.1565890
Vancouver
Wiktorowska‐Owczarek A, Iacono D, Jasińska-Stroschein M. Editorial: Old drugs: confronting recent advancements and challenges. Frontiers in Pharmacology. 2025. doi:10.3389/fphar.2025.1565890.
BibTeX
@article{anna2025Editor,
title = {Editorial: Old drugs: confronting recent advancements and challenges},
author = {Anna Wiktorowska‐Owczarek and Diego Iacono and Magdalena Jasińska-Stroschein},
journal = {Frontiers in Pharmacology},
year = {2025},
doi = {10.3389/fphar.2025.1565890},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2026
Open access · CC-BY
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
Aging cell 2026
Citation only
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
Biochemical Journal 2015
Preprint · CC-BY
Repurposing metformin: an old drug with new tricks in its binding pockets
Diabetes Obesity and Metabolism 2026
Open access · OA
Amino acid metabolism modulates chronic kidney disease progression by mediating the aging process: Mechanistic insights and therapeutic interventions
Cell Communication and Signaling 2024
Open access · CC-BY
Targeting cellular senescence in kidney diseases and aging: A focus on mesenchymal stem cells and their paracrine factors
Expert Reviews in Molecular Medicine 2023
Open access · CC-BY